BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 11313673)

  • 1. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
    Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
    Nakagawa M; Simizu Y; Suemura M; Sato B
    Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection.
    Ahmed A; Keeffe EB
    Am J Gastroenterol; 1999 Jan; 94(1):249-51. PubMed ID: 9934765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
    Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lamivudine for the prevention of chronic hepatitis B exacerbations during chemotherapy for non-Hodgkin's lymphoma].
    van der Eijk AA; Doorduijn JK; Janssen HL; Schalm SW; Niesters HG; de Man RA
    Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1140-4. PubMed ID: 12092307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
    Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
    J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
    Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
    Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
    Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.